{"date":"2025-10-06","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6677-2025-10-06-2212-qzkp9c","company_id":"6677","company":"瑩碩生技","market":"興櫃","industry":"生技醫療","date":"2025-10-06","time":"22:12:30","subject":"公告本公司治療思覺失調症505(b)(2)新藥AX251，通過美國食品藥物管理局(FDA)核准進行一期人體臨床試驗","clause":"第44款","fact_date":"2025-10-03","cite_as":"公開資訊觀測站重大訊息：瑩碩生技（6677），2025-10-06 22:12，「公告本公司治療思覺失調症505(b)(2)新藥AX251，通過美國食品藥物管理局(FDA)核准進行一期人體臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7759-2025-10-06-2026-1mak3cw","company_id":"7759","company":"視航生醫","market":"興櫃","industry":"生技醫療","date":"2025-10-06","time":"20:26:43","subject":"本公司眼藥水SHJ002-DED治療乾眼症三期臨床試驗申請，已完成美國FDA的人體臨床試驗審查(IND)送件","clause":"第8款","fact_date":"2025-10-06","cite_as":"公開資訊觀測站重大訊息：視航生醫（7759），2025-10-06 20:26，「本公司眼藥水SHJ002-DED治療乾眼症三期臨床試驗申請，已完成美國FDA的人體臨床試驗審查(IND)送件」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}